Clinical trials · New York
Polycythemia Vera clinical trials in New York
We’re tracking 10 recruiting polycythemia vera studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06093672RecruitingPhase 3
Comparing givinostat vs hydroxyurea for polycythemia vera
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
New York, New YorkAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
New York, New YorkAges 18 years+ - NCT07429266RecruitingPhase 3
Study of sapablursen for phlebotomy-dependent polycythemia vera
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
The Bronx, New YorkAges 18 years+ - NCT06343805RecruitingPhase 1
Study of AJ1-11095 for myelofibrosis after failed JAK2 inhibitor
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
New York, New YorkAges 18 years+ - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
New York, New YorkAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
New York, New YorkAges 18 years+ - NCT05714072RecruitingPhase 1
Ruxolitinib plus abemaciclib for myelofibrosis after ruxolitinib
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
Uniondale, New YorkAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
New York, New YorkAges 18 years+ - NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
New York, New YorkAges 18 years+ - NCT06541249RecruitingPhase 2
Adding methotrexate for blood cancers not controlled by current therapy
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
New York, New YorkAges 18 years+
Polycythemia Vera trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting polycythemia vera studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Montefiore Medical Center · 2 studies
- Ruttenberg Treatment Center · 2 studies
- Columbia University Irving Medical Center
- GSK Investigational Site
- Memorial Sloan Kettering Commack
- Memorial Sloan Kettering Nassau
What taking part in a polycythemia vera study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Polycythemia Vera trials in other states
Common questions
- Are there polycythemia vera clinical trials in New York?
- Yes. We're currently tracking 10 recruiting polycythemia vera studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a polycythemia vera study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a polycythemia vera trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New polycythemia vera studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.